Coste-efectividad de una solución bucal de midazolam en el tratamiento de las crisis convulsivas prolongadas en el entorno ambulatorio en España

This study assessed the safety and efficacy of buccal midazolam administered by caregivers for status epilepticus within the community setting. Pediatric patients who had previously tolerated and responded to buccally administered midazolam in a phase 3, hospital setting study (SHP615-301) were administered a single buccal midazolam dose by their trained caregiver in a community setting, following an episode of status epilepticus and before arriving at the hospital and/or emergency department. Three patients received treatment. All showed cessation of visible seizure activity within 5 minutes of treatment and absence of seizures 30 and 60 minutes after treatment. All treatmentemergent adverse events were mild, and no patients experienced respiratory depression. Caregivers reported satisfaction with the treatment experience. Buccally administered midazolam was well tolerated and effective for cessation of status epilepticus, and was safely and conveniently used by caregivers in the community setting in this study. (ClinicalTrials.gov identifier, NCT03336450)

show abstract

Buccal midazolam for treatment of pediatric status epilepticus in community settings in Japan: A phase 3 open-label extension study

Yoshinaga

Benitez

Takeda

et al. 2023

E&S

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Coste-efectividad de una solución bucal de midazolam en el tratamiento de las crisis convulsivas prolongadas en el entorno ambulatorio en España

Cited by 1 publication

References 0 publications

Buccal midazolam for treatment of pediatric status epilepticus in community settings in Japan: A phase 3 open-label extension study

Buccal midazolam for treatment of pediatric status epilepticus in community settings in Japan: A phase 3 open-label extension study

Contact Info

Product

Resources

About